Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. - Wikidata - wikimedia - TriplyDB

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q37422844

about

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Amino Acids in the Development of Prodrugs

P2860

Q33966365-FF67BD5F-12E1-4A83-962E-AC463FE573FE Q38060572-CB46D530-5F25-4D1E-80AA-FA04DC5213E8 Q58696356-8790312E-D147-4D2B-BACC-DAFA2836AA63

P2860

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q37422844

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@en

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@nl

type

label

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@en

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@nl

prefLabel

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@en

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@nl

P1433

Q37422844-1094CDAE-A183-4599-B93E-E56350D5143E

P1476

Q37422844-C43C8FCD-7F0F-4CDC-B4A9-131DA9107403

P2093

Q37422844-A31BE645-4336-4D2A-9F39-A41D074842DA

P2860

Q37422844-1D93444E-A0EB-4ABF-82B2-C89FDD7494C3

Q37422844-466180A6-87AE-4004-B60D-16ADEA01E8F7

Q37422844-79E0C621-A93E-4063-8B1C-32C9C340032F

Q37422844-815F9D50-70E4-4186-B462-5694976DA0FA

Q37422844-8C43830B-B418-489A-8941-A1544A67AEA1

Q37422844-92A31C24-0DF4-4921-BEC5-4409F093C5CB

Q37422844-935B26E0-B9C2-4ED4-BE0A-D15752DB8453

Q37422844-A70957AC-2453-4F28-A0D7-9901D9C00568

Q37422844-AE21279B-161D-4A0D-9230-7E07CDBD3D67

Q37422844-CE93A2FB-B78E-4FD2-9EE8-26081971366B

P304

Q37422844-B24ECE7D-061C-409E-838B-1AA3D7E24A22

P31

Q37422844-CF509B90-4D68-4923-826C-EAEE70BA5043

P356

Q37422844-F72D6CD3-7530-4DF8-B408-88C12AA05217

P407

Q37422844-0C31542E-6169-4960-B56B-7AC5B52F06AD

P433

Q37422844-605F97B3-19AD-4068-9FD3-D87E58A9DBE1

P478

Q37422844-149D7C2F-EC1A-4554-8679-CBBB97A378D5

P577

Q37422844-A9D724F1-C62B-4367-90DD-5D756D9A4A34

P698

Q37422844-080D0C60-CAC3-42F4-B640-E37B10BAB528

P921

Q37422844-4401C6E6-AE2D-45E8-AC2B-C8BEA6F99276

Q37422844-CD4C16AF-F94A-4649-9FFF-B6E4C4536A02

P356

P1433

Annals of Pharmacotherapy

P1476

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

@en

P2093

Brian J Cowles

http://www.w3.org/2001/XMLSchema#string

P2860

Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.

Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

P304

669-676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1L521

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19318601

http://www.w3.org/2001/XMLSchema#string

P921

attention deficit hyperactivity disorder